Morgane C. Mouslim, DVM, ScM

Real-world cross-validation of insurer and hospital price transparency data finds low overlap but high concordance between data sources.

This study leverages newly available hospital pricing data to explore hospital-insurer contracts from a large hospital chain.

Findings suggest that Basaglar was not less expensive for patients than Lantus. Empirical evaluation of biosimilar costs prior to automatic substitution is necessary.